Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why

SLNO shares surge as Neurocrine inks $2.9B cash deal to acquire it at $53 a share, adding Vykat XR and expanding its rare disease and endocrinology portfolio.

Go to News Site